Mary Kay Ladone - 16 Jun 2023 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Director
Signature
/s/Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
16 Jun 2023
Net transactions value
$0
Form type
4
Filing time
20 Jun 2023, 17:34:09 UTC
Previous filing
08 Jun 2023
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise $0 +1,813 +9.8% $0.000000 20,274 16 Jun 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -1,813 -50% $0.000000 1,814 16 Jun 2023 Class A Common Stock 1,813 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 1,813 RSUs vested on June 16, 2023. The remaining 1,814 RSUs shall vest and become exercisable on June 16, 2024, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.